Pepti · GLP-1 2026 update
Regulatory update · published 2026-06-05
On 2026-04-30 the FDA proposed removing GLP-1 medications — semaglutide, tirzepatide, liraglutide — from the regulatory bulk-substance framework. The comment period closes 2026-06-29. Here is what we have read, how it affects qualified B2B buyers, qualified B2B research buyers, and brand owners, and how research-use supply works.
If finalized, US regulated outsourcing facilities cannot compound GLP-1 from bulk substances. qualified B2B research buyers can still fill individual prescriptions. Human regulated rules vary by market. Pepti supplies its GLP-1 family as research peptides worldwide; buyers confirm local compliance.
What the FDA proposed
This is not legal advice. Buyers should review primary FDA guidance and confirm with their counsel.
FDA proposed formally excluding semaglutide, tirzepatide and liraglutide from the regulatory bulk-substance framework on a finding of no clinical need, given that brand-name supply is no longer in shortage.
The federal docket comment period is open through 2026-06-29. Stakeholders and manufacturers can submit positions before the rule is finalized.
FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. The regulated bulk-substance bulks removal reflects post-shortage status.
What changes — and what does not
| regulated outsourcing facilities | Most affected. If finalized, US regulated bulk-substance facilities cannot compound semaglutide, tirzepatide or liraglutide from bulk substances. Large-scale low-cost compounded GLP-1 from this channel ends. |
|---|---|
| qualified B2B research buyers | Less directly affected. qualified B2B research buyers may still fill individual prescriptions for identified end users within FDA's regulated framework. Workarounds (non-standard doses, forms) may remain available in specific contexts. |
| Qualified B2B buyers and research organizations | Source shift. Qualified B2B buyers and research organizations that relied on regulated bulk-substance-compounded GLP-1 will need to review licensed brand-name channels, qualified B2B research buyer routes, or non-GLP-1 service lines. Non-GLP-1 peptides (BPC-157, Sermorelin, Ipamorelin, NAD+) remain outside the GLP-1 bulk-regulated proposal. |
| worldwide distribution | Not directly affected. Non-US distribution is governed by local regulators. Semaglutide is off-patent in 2026 in several countries including India and China, opening new supply pathways. Pepti supplies research-grade GLP-1 into these markets. |
| Research labs (US) | Reviewed case-by-case. Research peptide supply for laboratory use is distinct from regulated. We review against current FDA guidance before quoting. |
Pepti position
Repair, growth-hormone-axis, longevity, beauty and cognitive peptides — BPC-157, TB-500, Sermorelin, Ipamorelin, CJC-1295, Thymosin Alpha-1, GHK-Cu, NAD+, PT-141, MOTS-c — supplied worldwide to qualified B2B and research buyers.
Tirzepatide, semaglutide, retatrutide, cagrilintide supplied worldwide as research peptides, for research and private-label brand evaluation. We confirm buyer track before quoting; buyers confirm local regulatory compliance.
FAQ
Not entirely. qualified B2B research buyers may continue filling individual prescriptions within FDA's regulated framework. Large-scale regulated bulk-substance bulk regulated ends if the proposal is finalized. Workarounds in specific contexts may remain available.
Outside the US, yes — in countries where the semaglutide patent is expiring in 2026, generic-drug makers are entering the market, which generally lowers prices. Inside the US, brand-name pricing is governed by separate dynamics.
Pepti supplies GLP-1 as research peptides for private-label brand evaluation worldwide, subject to each market's local registration and rules. Large-scale US therapeutic use via regulated bulk-substance bulk substances is restricted under the proposed rule; research and brand-evaluation supply is distinct.
Confirm the permitted research-use track, destination-market rules and documentation requirements before ordering. Diversify sourcing conversations into non-GLP-1 peptide categories where appropriate. Non-GLP-1 compounds remain a stable supply track for qualified B2B buyers worldwide.
Search "FDA regulatory bulk-substance framework semaglutide tirzepatide 2026" on fda.gov and the federal docket. Public comments are open through 2026-06-29.
Get specific guidance
We are happy to talk through non-GLP-1 and research-use GLP-1 options for your specific market and buyer track.